The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
In β− decay, the weak interaction converts an atomic nucleus into a nucleus with atomic number increased by one, while emitting an electron (e−) and an electron antineutrino (νe). β− decay generally occurs in neutron-rich nuclei. The generic equation is:
=== Pre-release === Before being preempted by its bigger sister label TriStar, the film was intended for release by Ben Ami's Triumph Releasing. The release date was originally pegged for January 1991, or February after the film's partial reboot in July. The first full release date to be floated around was May 3, 1991. The original cut was given an NC-17 rating, in what was claimed to be a first for an action film. The producers immediately assured that they were committed to securing an R rating, and edits were made accordingly. Bosworth embarked on an eight-city tour to promote the film, which avoided Seattle. The Seahawks refused to field media inquiries about their former player in the run-up to Stone Cold's release. The film's premiere took place at Universal Studios on May 16, 1991. In keeping with the film's tone, invitations bore the mention "No suits allowed", and Wichard chartered 250 Harley Davidsons, allowing some of the approximately 800 guests to ride two-up to the venue. The boisterous Wichard publicly denigrated other action stars for their advancing age and Arnold Schwarzenegger for looking awkward in a publicity shot as a biker. Bosworth floated the idea of changing his name to Bozworth, an allusion to his football nickname "The Boz", before conceding that it was another of his manager's publicity stunts. Wichard also pushed for the title change from The Brotherhood to Stone Cold to better emphasize his client.
Federal agencies in the United States, such as the National Institute of Health (NIH) and National Science Foundation (NSF), have also funded research that pertains to best practices in teaching and learning of neuroscience concepts.
A presentation seen during gameplay reveals that GLaDOS was included in a proposed bid for de-icing fuel lines, incorporated as a fully functional disk-operation system that is arguably alive, unlike Black Mesa's proposal, which inhibits ice, nothing more. After contracting a terminal illness from moon rocks used in portal experiments, Cave decides to attempt to back up his consciousness to a computer. He realises that the technology will not be ready in time to backup his brain due to his imminent demise, and leaves instructions to forcefully backup the consciousness of his assistant Caroline. Upon being uploaded to GLaDOS, Caroline attempts to kill every scientist in the building in under a fraction of a second. After extensive attempts to control her with smaller robots called personality spheres that would act as emotional limits and a sort of artificial "conscience", GLaDOS managed to eventually convince the scientists that she was primarily concerned with science and requested a lethal brain neurotoxin for an experiment about cats. GLaDOS initiated the experiment during the company's first annual bring-your-daughter-to-work day in 1998. Immediately after activation, the facility was flooded with deadly neurotoxin by the AI. Events of the first Half-Life game occur shortly after that, presumably leaving the facility forgotten by the outside world due to apocalyptic happenings. Wolpaw, in describing the ending of Portal 2, affirmed that the Combine invasion, chronologically taking place after Half-Life and before Half-Life 2, had occurred before Portal 2's events.
Sources: en.wikipedia.org
=== Defunct === Liaison Committee for a Revolutionary Workers International, founded by former militants of the Argentinian MAS and PO Committee for a Workers' International (CWI), 1974–2019 – split into Committee for a Workers' International (Refounded) and International Socialist Alternative Coordinating Committee for the Refoundation of the Fourth International, CCRCI (2004-2020) International League for the Reconstruction of the Fourth International (ILRFI), 1976–1995 Workers International to Rebuild the Fourth International (WIRFI) International Revolutionary Marxist Tendency (TMRI), 1965–1992 Permanent Revolution Revolutionary Workers Ferment (Fomento Obrero Revolucionario, FOR) Trotskyist International Liaison Committee, 1979–1984 Tendencia Cuartainternacionalista Fourth International (ICR), also called FI (La Verité) or FI (International Secretariat) 1981–2015 Socialist Network (Post-Trotskyist, split from IMT) International Trotskyist Opposition] (ITO) 2022–2025 (Dissolved into LIS-ISL) League for the Fifth International (L5I), founded by expelled members of the IST. (1989-2025)
=== Host range === The host range of the bacterium is mainly domestic dogs but evidence of infections in foxes and coyotes has been reported. B. canis is a zoonotic organism and although rare, humans can contract the infection. It is unlikely, but most common in dog breeders, those in laboratories dealing with the bacteria, or people who are immunocompromised.
== Dosage and administration == Each benzhydrocodone/APAP immediate release tablet contains 6.12 mg of benzhydrocodone (equivalent to 6.67 mg of benzhydrocodone hydrochloride) and 325 mg of acetaminophen. The tablets are white, capsule-shaped and are debossed with "KP201" on one side. Dosing should start at one to two tablets every four to six hours, as needed for pain. The dosage should not exceed 12 tablets in a 24-hour period. The total dosage of benzhydrocodone/APAP and any other acetaminophen containing products should not exceed 4000 mg of acetaminophen in a 24-hour period.
The classical, histopathological definition of amyloid is an extracellular, proteinaceous fibrillar deposit exhibiting β-sheet secondary structure and identified by apple-green birefringence when stained with congo red under polarized light. These deposits often recruit various sugars and other components such as serum amyloid P component, resulting in complex, and sometimes inhomogeneous structures. Recently this definition has come into question as some classic, amyloid species have been observed in distinctly intracellular locations. A more recent, biophysical definition is broader, including any polypeptide that polymerizes to form a cross-β structure, in vivo or in vitro, inside or outside cells. Microbiologists, biochemists, biophysicists, chemists and physicists have largely adopted this definition, leading to some conflict in the biological community over an issue of language.
SNX contains a BAR domain in its C-terminus, which is located between amino acids 256 and 440. Its ability to form coatings in membranes in order to induce their curvature is key in SNX8 participation in tubular structures formation. Furthermore, SNX8 C-terminus contains a threonine in position 452 and a serine in position 456 which can go through post-traductional changes that induces its phosphorylation, resulting in a phosphothreonine and a phosphoserine. Therefore, there are classified as phosphorylation sites. SNX8 has a yeast ortholog protein, the MVP1 encoded by the also homolog gene Mvp1p, which also plays a role by mediating transport of cargo to the vacuolar and lysosomal compartments. For this reason, its investigation can lead to a better understanding of SNX8 functions in human cells.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.